BioTrack Capital, a dedicated healthcare venture capital firm, led a $19.2m funding round in Cargene, a preclinical-stage biopharmaceutical company, with particiption from Hyfinity Investments, Legendstar Capital and others. "Cargene reflects EVX's philosophy to invest in technologies that redefine the therapeutics of tomorrow. The cross border scientific ecosystems that Cargene is built upon will help fully realize oligonucleotides' therapeutic potential and create long-lasting and meaningful impact for patients worldwide," XQ Lin, Cargene Chairman.